SelK-2 is under clinical development by Tetherex Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SelK-2’s likelihood of approval (LoA) and phase transition for Asthma took place on 09 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 09 Feb 2022 decreased SelK-2’s LoA and PTSR for Chronic Obstructive Pulmonary Disease (COPD).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SelK-2 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SelK-2 overview

SelK-2 is under development for the treatment of venous thromboembolism in patients undergoing total knee replacement surgery, asthma, chronic obstructive pulmonary disease, Crohn's disease. It is administered through intravenous route. It is a fully human monoclonal antibody that acts by targeting P-selectin glycoprotein ligand-1 (PSGL-1). It was also under development for the treatment of multiple myeloma (Kahler's disease) and other inflammatory disorders.

Tetherex Pharmaceuticals overview

Tetherex Pharmaceuticals is a biopharmaceutical company that develops novel medicines for inflammation, thrombosis and tumor metastasis. It is investigating its lead product candidate SelK2, a humanized monoclonal antibody directed against P-Selectin Glycoprotein Ligand-1 (PSGL-1) molecule by blocking its interaction with P and L selectin family of molecules, and chemokine’s to treat Crohn’s disease and venous thromboembolism. Tetherex Pharmaceuticals is a spin-off from Selexys Pharmaceuticals Corp. The company operates office in Morrisville, North Carolina, the US. Tetherex Pharmaceuticals is headquartered in Oklahoma, the US.

Quick View SelK-2 LOA Data

Report Segments
  • Innovator
Drug Name
  • SelK-2
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Immunology
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.